Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zevra Therapeutics

Request full access

Targeting improved therapies for pain, ADHD and other CNS indications

Boston, United StatesFounded 2006Biotech & Life Sciences

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a biopharmaceutical company that has carved out a niche in the rare disease market by focusing on therapies for conditions with substantial unmet medical needs. The company, which trades under the ticker ZVRA, was formerly known as KemPharm, Inc. before a strategic rebranding in February 2023 to better reflect its sharpened focus on rare diseases. This transition was spearheaded by the leadership team, including CEO Neil F. McFarlane, as the company pivoted to concentrate its resources on developing and commercializing treatments for select rare CNS disorders and other rare conditions.

The company's business model centers on acquiring, developing, and commercializing novel treatments. A key asset in its portfolio is azstarys, a once-daily product for the treatment of ADHD in patients aged six years and older, which is partnered with Corium, Inc. for commercialization in the U.S. Revenue is generated through various streams, including product sales, royalty payments, and milestone achievements from its commercial partnerships. The company's primary commercial product is OLPRUVA™, a treatment for urea cycle disorders (UCDs), which became part of its portfolio following the acquisition of Acer Therapeutics.

Zevra's development pipeline is a core component of its valuation, featuring arimoclomol as a potential treatment for Niemann-Pick disease type C (NPC). The company has been actively engaging with regulatory bodies, including the U.S. Food and Drug Administration (FDA), to navigate the approval process for its drug candidates. Its operational strategy involves a combination of in-house development and strategic acquisitions, allowing it to build a portfolio of differentiated product candidates aimed at patient populations that are often overlooked by larger pharmaceutical firms. The company targets physicians, patients, and advocacy groups, involving them in its clinical development to ensure its therapies meet real-world needs.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015
Employees
78
Open positions
14
Dealroom signal
83.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Pediatrics, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
2 companies, latest Aug 2023
Capital deployed
—
Preferred round
ACQUISITION

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Aug 2024 $60M — Undisclosed ↗
POST IPO DEBT✓Debt Apr 2024 $100M — HealthCare Royalty · Perceptive Advisors ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Zevra Therapeutics website traffic

Latest recorded traffic for Zevra Therapeutics is 13K monthly website visits, up 49.4% over the last three months. Zevra Therapeutics's team declined 2.5% over the past year.

Latest monthly visits13K 3-month web change+49.4% 1-year team growth-2.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Zevra Therapeutics in the Boston ecosystem

Live from Dealroom

The Zevra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • BP Growth Partners

Series B and later3 investors entered at this stage

Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States91.4%
🇩🇰 Denmark5.2%
🇬🇧 United Kingdom1.7%
🇩🇪 Germany1.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zevra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zevra Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.